Galderma’s Relfydess™ (relabotulinumtoxinA) Receives Approval in China for Frown Lines
Financial Post ·
The Chinese National Medical Products Administration (NMPA) has approved Relfydess™, the first and only ready-to-use liquid neuromodulator designed with PEARL™ Technology, for the temporary improvement of moderate-to-severe glabellar lines (frown lines) in adults1,2 The approval is based on phase III results from a local clinical trial conducted in China as well as global READY clinical […]
ZUG, Switzerland -- Galderma (SIX: GALD) today announced that the Chinese NMPA has approved Relfydess for the temporary improvement of moderate-to-severe frown lines in adults, marking a significant expansion of the company’s Injectable Aesthetics portfolio in China – one of the world's largest and fastest-growing aesthetics markets. 8,9 This approval follows successful authorizations and launches of Relfydess in more than 35 markets worldwide. Read More